Literature DB >> 2509743

The economic costs of non-insulin-dependent diabetes mellitus.

D M Huse1, G Oster, A R Killen, M J Lacey, G A Colditz.   

Abstract

Persons with diabetes experience elevated risks of a variety of other illnesses-- including circulatory, visual, neurological, renal, and skin disorders--relative to their nondiabetic peers. Previous estimates of the economic burden of diabetes, however, have not taken full account of this related morbidity and mortality and have therefore understated the cost to the nation due to this disease. Accordingly, we estimated the economic costs of type II, or non-insulin-dependent, diabetes mellitus, reflecting its contribution to the total burden of disease in the United States. In 1986, non-insulin-dependent diabetes mellitus was responsible for $11.6 billion in health care expenditures, including $6.8 billion for diabetic care and $4.8 billion attributable to an excess prevalence of related (principally cardiovascular) conditions. The human toll of non-insulin-dependent diabetes mellitus included 144,000 deaths -- about 6.8% of total US mortality -- and the total disability of 951,000 persons. The total economic burden of non-insulin-dependent diabetes mellitus in 1986, including health care expenditures and productivity forgone due to disability and premature mortality, was $19.8 billion.

Entities:  

Mesh:

Year:  1989        PMID: 2509743     DOI: 10.1001/jama.262.19.2708

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 2.  Screening for diabetes in pregnancy.

Authors:  S Virjee; S Robinson; D G Johnston
Journal:  J R Soc Med       Date:  2001-10       Impact factor: 5.344

3.  The cost of obesity: the US perspective.

Authors:  A M Wolf; G A Colditz
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

4.  The cost of migraine: more than just a headache?

Authors:  P J Davey; S R Leeder
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 5.  Global healthcare financing for type II diabetes: are there ways out of the crisis?

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

6.  Painful neuropathic disorders: an analysis of the Régie de l'Assurance Maladie du Québec database.

Authors:  J Lachaine; A Gordon; M Choinière; J P Collet; D Dion; J-E Tarride
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

7.  Utility of hemoglobin A1c in predicting diabetes risk.

Authors:  David Edelman; Maren K Olsen; Tara K Dudley; Amy C Harris; Eugene Z Oddone
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

8.  The cost effectiveness of Apligraf treatment of diabetic foot ulcers.

Authors:  W Ken Redekop; Joseph McDonnell; Paul Verboom; Kornelia Lovas; Zoltan Kalo
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Assessing the impact of complications on the costs of Type II diabetes.

Authors:  R Williams; L Van Gaal; C Lucioni
Journal:  Diabetologia       Date:  2002-07       Impact factor: 10.122

10.  Coping with Type II diabetes: the patient's perspective.

Authors:  M Koopmanschap
Journal:  Diabetologia       Date:  2002-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.